The levels of serum pro-calcitonin and high-sensitivity C-reactive protein in the early diagnosis of chronic obstructive pulmonary disease during acute exacerbation

Gao,Dejie; Chen,Xincan; Wu,He; Wei,Haidong; Wu,Jinling

doi:10.3892/etm.2017.4496

The levels of serum pro-calcitonin and high-sensitivity C-reactive protein in the early diagnosis of chronic obstructive pulmonary disease during acute exacerbation

Authors:
- Dejie Gao
- Xincan Chen
- He Wu
- Haidong Wei
- Jinling Wu
View Affiliations

Affiliations: Department of Tuberculosis, Binzhou Tuberculosis Control Center, Binzhou Medical College, Binzhou, Shandong 250000, P.R. China, Department of Laboratory, Binzhou Center Hospital, Binzhou Medical College, Binzhou, Shandong 256603, P.R. China, Department of Respiratory Medicine, Binzhou Center Hospital, Binzhou Medical College, Huimin, Shandong 251700, P.R. China
Published online on: May 23, 2017 https://doi.org/10.3892/etm.2017.4496
Pages: 193-198
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The level of of procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in the acute exacerbation of COPD (AECOPD) was investigated. Total of 20 patients with acute exacerbation of COPD who were admitted to the Department of Respiratory Medicine, Binzhou Center Hospital in the period of October 2012 to April 2015 were enrolled in the AECOPD group. According to the color of the sputum, the patients with AECOPD were divided into purulent sputum group (n=8) and non-purulent sputum group (n=12). In addition, 15 healthy people from the outpatient medical center were also selected as healthy control group. The levels of serum PCT and hs-CRP in both groups were determined by chemiluminescence and immunoturbidimetry, respectively for the comparison analysis. The serum PCT concentration in AECOPD group was 2.07±5.57 ng/ml, while that in healthy control group was 0.21±0.17 ng/ml. Significant difference was found between serum PCT levels in the two groups (p<0.05). The serum concentration of hs-CRP in AECOPD group was 3.66±3.95 mg/l, which is significantly higher than that of the healthy control group (0.49±0.17) (p<0.001). In AECOPD group, the sensitivity of PCT, hs-CRP and white blood cell count was 75, 40 and 40%, respectively, while the specificity was 80, 100 and 100%, respectively, indicating that PCT has higher sensitivity than hs-CRP and white blood cell count (p<0.05). However, no significant difference was found in specificity among these three methods (p>0.05). PCT level of the patients in purulent sputum group was 3.72±8.80 ng/ml, while that of the patients in non-purulent sputum group was 0.97±1.06 ng/ml. The serum hs-CRP level of patients in purulent sputum group was 4.94±4.60 mg/l, while that of the patients in non-purulent sputum group was (2.80±3.38 mg/l). Both the above parameters showed no significant difference between the purulent sputum group and the non-purulent sputum group (p>0.05). In conclusion, serum PCT and hs-CRP levels can be used as auxiliary diagnosis index for acute exacerbation of COPD. Measurement of serum PCT and hs-CRP levels in patients with AECOPD may be helpful in guiding antibacterial drug therapy.

View Figures

View References

1	Sethi S: Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 26:192–203. 2005. View Article : Google Scholar : PubMed/NCBI
2	Hirschmann JV: Do bacteria cause exacerbations of COPD? Chest. 118:193–203. 2000. View Article : Google Scholar : PubMed/NCBI
3	Murphy TF and Sethi S: Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 146:1067–1083. 1992. View Article : Google Scholar : PubMed/NCBI
4	Monsó E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J and Ausina V: Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 152:1316–1320. 1995. View Article : Google Scholar : PubMed/NCBI
5	Burrows B and Earle RH: Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med. 280:397–404. 1969. View Article : Google Scholar : PubMed/NCBI
6	Sohy C, Pilette C, Niederman MS and Sibille Y: Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: What studies are still needed? Eur Respir J. 19:966–975. 2002. View Article : Google Scholar : PubMed/NCBI
7	Nylén ES, Snider RH Jr, Thompson KA, Rohatgi P and Becker KL: Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 312:12–18. 1996. View Article : Google Scholar : PubMed/NCBI
8	Nijsten MW, Olinga P, The TH, De Vries EG, Koops HS, Groothuis GM, Limburg PC, ten Duis HJ, Moshage H, Hoekstra HJ, et al: Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 28:458–461. 2000. View Article : Google Scholar : PubMed/NCBI
9	Somech R, Zakuth V, Assia A, Jurgenson U and Spirer Z: Procalcitonin correlates with C-reactive protein as an acute-phase reactant in pediatric patients. Isr Med Assoc J. 2:147–150. 2000.PubMed/NCBI
10	Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J and Bohuon C: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 341:515–518. 1993. View Article : Google Scholar : PubMed/NCBI
11	Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W and Ritz R: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 28:977–983. 2000. View Article : Google Scholar : PubMed/NCBI
12	Vincent JL: Procalcitonin: THE marker of sepsis? Crit Care Med. 28:1226–1228. 2000. View Article : Google Scholar : PubMed/NCBI
13	Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:499–511. 2003. View Article : Google Scholar : PubMed/NCBI
14	Lin KH, Wang FL, Wu MS, Jiang BY, Kao WL, Chao HY, Wu JY and Lee CC: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: A systematic review and meta-analysis. Diagn Microbiol Infect Dis. 80:72–78. 2014. View Article : Google Scholar : PubMed/NCBI
15	Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS and Wenzel RP: The natural history of the systemic inflammatory response syndrome(SIRS). A prospective study. JAMA. 273:117–123. 1995. View Article : Google Scholar : PubMed/NCBI
16	Shimetani N, Ohba Y, Shimetani K, Mashiko T, Matsuyama N, Ohtani H and Morii M: Assay for determination of the serum procalcitonin level: Biochemical and clinical evaluation. Rinsho Byori. 49:56–60. 2001.(In Japanese). PubMed/NCBI
17	Lieberman D, Lieberman D, Shmarkov O, Gelfer Y, Ben-Yaakov M, Lazarovich Z and Boldur I: Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur Respir J. 19:392–397. 2002. View Article : Google Scholar : PubMed/NCBI
18	Peng C, Tian C, Zhang Y, Yang X, Feng Y and Fan H: C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci. 345:190–194. 2013. View Article : Google Scholar : PubMed/NCBI
19	Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G and Lode H: Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 21:939–943. 2003. View Article : Google Scholar : PubMed/NCBI
20	Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Müller B and Tamm M: Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 136:434–440. 2006.PubMed/NCBI
21	Pazarli AC, Koseoglu HI, Doruk S, Sahin S, Etikan I, Celikel S and Berktas B: Procalcitonin: Is it a predictor of noninvasive positive pressure ventilation necessity in acute chronic obstructive pulmonary disease exacerbation? J Res Med Sci. 17:1047–1051. 2012.PubMed/NCBI
22	Tanrıverdi H, Örnek T, Erboy F, Altınsoy B, Uygur F, Atalay F and Tor MM: Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr. 127:756–763. 2015. View Article : Google Scholar : PubMed/NCBI
23	Yeh ET and Willerson JT: Coming of age of C-reactive protein: Using inflammation markers in cardiology. Circulation. 107:370–371. 2003. View Article : Google Scholar : PubMed/NCBI
24	Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG and Emmanuel FX: Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 92:664–667. 1998. View Article : Google Scholar : PubMed/NCBI
25	Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS and Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 174:867–874. 2006. View Article : Google Scholar : PubMed/NCBI
26	Bircan A, Gokirmak M, Kilic O, Ozturk O and Akkaya A: C-reactive protein levels in patients with chronic obstructive pulmonary disease: Role of infection. Med Princ Pract. 17:202–208. 2008. View Article : Google Scholar : PubMed/NCBI
27	Stockley RA, OBrien C, Pye A and Hill SL: Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 117:1638–1645. 2000. View Article : Google Scholar : PubMed/NCBI
28	Gompertz S, O'Brien C, Bayley DL, Hill SL and Stockley RA: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 17:112–1119. 2001. View Article : Google Scholar
29	Monsó E, Garcia-Aymerich J, Soler N, Farrero E, Felez MA, Antó JM and Torres A: EFRAM Investigators: Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 131:799–804. 2003. View Article : Google Scholar : PubMed/NCBI
30	Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B and Tamm M: Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 131:9–19. 2007. View Article : Google Scholar : PubMed/NCBI
31	Weis N and Almdal T: C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 17:88–91. 2006. View Article : Google Scholar : PubMed/NCBI